NAMS Stock Overview
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
NewAmsterdam Pharma Company N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$19.58 |
52 Week High | US$26.35 |
52 Week Low | US$5.63 |
Beta | 0.081 |
1 Month Change | -8.72% |
3 Month Change | -15.38% |
1 Year Change | 48.56% |
3 Year Change | 100.20% |
5 Year Change | n/a |
Change since IPO | 81.30% |
Recent News & Updates
Shareholder Returns
NAMS | US Biotechs | US Market | |
---|---|---|---|
7D | -2.3% | 0.07% | -0.2% |
1Y | 48.6% | 6.9% | 28.2% |
Return vs Industry: NAMS exceeded the US Biotechs industry which returned 6.9% over the past year.
Return vs Market: NAMS exceeded the US Market which returned 28.2% over the past year.
Price Volatility
NAMS volatility | |
---|---|
NAMS Average Weekly Movement | 7.7% |
Biotechs Industry Average Movement | 11.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NAMS has not had significant price volatility in the past 3 months.
Volatility Over Time: NAMS's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 40 | Michael Davidson | www.newamsterdampharma.com |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease.
NewAmsterdam Pharma Company N.V. Fundamentals Summary
NAMS fundamental statistics | |
---|---|
Market cap | US$1.76b |
Earnings (TTM) | -US$228.69m |
Revenue (TTM) | US$6.86m |
256.8x
P/S Ratio-7.7x
P/E RatioIs NAMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NAMS income statement (TTM) | |
---|---|
Revenue | US$6.86m |
Cost of Revenue | US$0 |
Gross Profit | US$6.86m |
Other Expenses | US$235.55m |
Earnings | -US$228.69m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.54 |
Gross Margin | 100.00% |
Net Profit Margin | -3,332.64% |
Debt/Equity Ratio | 0% |
How did NAMS perform over the long term?
See historical performance and comparison